Pfizer (NYSE:PFE) Reaches New 1-Year Low at $25.26

Shares of Pfizer Inc. (NYSE:PFE) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $25.26 and last traded at $25.30, with a volume of 19767977 shares trading hands. The stock had previously closed at $25.42.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Up 2.4 %

The company has a market cap of $147.17 billion, a P/E ratio of 72.19, a PEG ratio of 1.14 and a beta of 0.61. The stock’s 50-day moving average price is $27.11 and its 200-day moving average price is $28.68. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.14 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently made changes to their positions in PFE. RB Capital Management LLC raised its holdings in shares of Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. increased its stake in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares during the last quarter. United Bank increased its stake in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the last quarter. Ergoteles LLC increased its stake in Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp increased its stake in Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.